Could a simple heart pill boost lung cancer treatment?

NCT ID NCT05387512

Completed Knowledge-focused Sponsor: Affiliated Hospital of Nantong University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked back at medical records of 60 people with advanced non-small cell lung cancer who received standard immunotherapy (anti-PD-1/PD-L1 drugs). Researchers checked whether those who also took beta-blockers (commonly used for heart conditions) had different outcomes, like how long the cancer stayed under control. The goal is to see if this common heart medication might influence how well immunotherapy works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: beta-blocker (concomitant exposure during anti-PD-1/PD-L1 therapy)
What this could lead to: If beta-blockers are linked to better outcomes, this could point toward a simple, low-cost way to boost immunotherapy effectiveness in lung cancer.
What could go wrong: This is a small, retrospective observational study, not a controlled trial. It can only show an association, not cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Department of Pharmacy, Affiliated Hospital of Nantong University

Nantong, Jiangsu, 226000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.